Senseonics Eversense E3 Ascensia Diabetes Care
The Eversense E3 system. [Image from Ascensia/Senseonics]

Senseonics (NYSE:SENS) shares were up after hours today on second-quarter results that came up shy of the consensus forecast.

The Germantown, Maryland-based continuous glucose monitoring technology developer posted profits of $103.9 million, or 22¢ per share, on sales of $3.7 million for the three months ended June 30, 2022, for a massive bottom-line gain from losses of more than $180 million this time last year on sales growth of 12.9%.

Get the full story at our sister site, Drug Delivery Business News.